SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a 1.4 billion dollar convertible debt exchange for equity, a move that has sparked intense debate among investors regarding strategic balance sheet cleanup versus shareholder dilution. The community remains deeply polarized, with vocal bears criticizing management's capital allocation and retail investors debating whether this sets the stage for a potential acquisition or further long-term volatility.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is experiencing significant volatility and heavy volume as traders react to a critical FDA advisory committee meeting concerning its cancer therapy candidate. The stock is a major focal point for speculative betting, with intense community debate over potential approval, short interest dynamics, and the high-stakes binary outcome surrounding an impending PDUFA date.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending as investors position themselves ahead of the company's highly anticipated earnings report, with the community closely watching for updates on fleet expansion, operational scaling, and real-world utilization metrics. Traders are actively debating the stock's significant short interest and the potential for a gamma squeeze, while weighing the company's long-term physical AI growth thesis against current macro-economic volatility.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging as investor confidence grows around the rapid commercial success of Briumvi and the strategic expansion of its pipeline into treatment-resistant schizophrenia and myasthenia gravis. The community is actively discussing the stock's potential as a major buyout target for Big Pharma, with many dismissing conservative analyst price targets as disconnected from the company's strong growth trajectory and successful commercial execution.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to the company's recent AI-driven digital innovation announcements and active share buyback program. The community remains focused on potential relisting catalysts, store expansion metrics, and the company's competitive standing against legacy coffee chains.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE CRYPTO is currently a focal point for investors due to its innovative revenue-sharing model, which uses platform fees to systematically burn supply, and its growing utility as a decentralized alternative for trading pre-IPO stocks and real-world assets. The community is actively debating the sustainability of these high-volume dynamics versus broader market volatility, with many users tracking fee-burn data in real-time as a primary indicator for potential accumulation.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz as investors eagerly await Phase 3 data from the IZAR-1 trial for psoriatic arthritis, with many viewing the company's recent capital raise and institutional backing as evidence of long-term confidence in its nanobody pipeline. Community discourse is heavily focused on the high-stakes 'about a month' timeline set by management, fueling a mix of intense anticipation for best-in-class efficacy results and debates over the timing of potential catalysts versus earnings.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is capturing significant market attention following a high-profile global licensing agreement with Janux Therapeutics to expand its oncology pipeline and a series of promising updates from its late-stage development programs. The community is actively discussing the stock's defensive appeal as a dividend player, while weighing the balance between the company's aggressive R&D pivot to address upcoming patent expirations and its current defensive market positioning.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing a sustained, momentum-driven rally that the community is actively debating as either a genuine recovery fueled by easing geopolitical tensions or a persistent, artificial "scam pump" orchestrated by market makers. Investors remain divided and cautious, with heavy community focus on the absence of expected pullbacks, the disconnect between market behavior and underlying volatility, and the looming uncertainty surrounding upcoming jobs data and broader economic risks.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is drawing intense investor focus as the stock experiences high volatility following a series of conflicting analyst price target adjustments, leaving the community divided on whether to buy the dip or brace for further downside. Market participants are actively debating the sustainability of its premium valuation amidst a broader semiconductor pullback, while monitoring its strategic role in the evolving AI infrastructure and data center compute cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
